「assess」の検索結果

Analyzes malicious Linux ELF (Executable and Linkable Format) binaries including botnets, cryptominers, ransomware, and rootkits targeting Linux servers, containers, and cloud infrastructure. Covers static analysis, dynamic tracing, and reverse engineering of x86_64 and ARM ELF samples. Activates for requests involving Linux malware analysis, ELF binary investigation, Linux server compromise assessment, or container malware analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Scan agent skills for security issues. Use when asked to "scan a skill", "audit a skill", "review skill security", "check skill for injection", "validate SKILL.md", or assess whether an agent skill is safe to install. Checks for prompt injection, malicious scripts, excessive permissions, secret exposure, and supply chain risks.

日本語の概要は準備中です。原文の説明を表示しています。

How to explore and make sense of PostHog Signals scouts — the scheduled agents that scan a project and emit findings into the Signals inbox. Use when a user wants to understand what scouts they have, how each one is behaving, and whether the fleet is actually working. Covers surveying the fleet and its schedules, reading recent scout runs and drilling into a single run's reasoning, inspecting the durable scratchpad memory the fleet has built up, tracing a run to the findings it emitted, and assessing a scout's health and performance over time (cadence, success rate, emit rate, signal-to-noise). Read-only and exploratory — to write or tune a scout, use `authoring-signals-scouts` instead. Trigger on "what are my scouts doing", "how is my <x> scout performing", "show me recent scout runs", "why did this scout find/emit nothing", "what has the fleet learned", "explore scout run <id>", "is my scout working".

日本語の概要は準備中です。原文の説明を表示しています。

Synthesize scientific evidence into a claim-to-source matrix, distinguish primary evidence from interpretation, assess disagreement and study limitations, and produce a calibrated research summary.

日本語の概要は準備中です。原文の説明を表示しています。

Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.

日本語の概要は準備中です。原文の説明を表示しています。

Solve quantitative problems in biophysics — pharmacokinetics (PK volume of distribution, clearance, half-life), epidemiology (R0, attack rate), toxicology (LD50, NOAEL), population genetics (Hardy-Weinberg, Fst), enzyme kinetics (Michaelis-Menten), thermodynamics. Use for first-principles quantitative biology calculations, dose calculations, exposure assessment, and biophysical-property estimation.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluate LLM outputs using frontier models as judges. Use for pairwise model comparison, quality scoring with custom rubrics, and automated evaluation pipelines. Covers position bias mitigation, statistical significance, and generating preference data for DPO/RLHF.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates an end-to-end CRISPR editing experiment design from target gene to delivery-ready, validatable constructs. Sequences guide design, off-target assessment, edit-modality selection (knockout, base editing, prime editing, HDR knock-in), and template/donor design, with a QC checkpoint at each handoff. Use when designing a complete CRISPR experiment for knockout, point correction, or tagging and the order of operations, the modality decision, and the cross-cutting traps are needed rather than a single step. Defers each step's mechanics to the genome-engineering skills.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end eDNA metabarcoding from raw amplicons to community ecology. Covers QC, primer removal (mandatory before DADA2 filterAndTrim), denoising with OBITools3 v3 (obi stats plural; DMS-based) or DADA2 ASVs (Callahan 2017), decontam combined method as screening-not-classifier (Davis 2018), tag-jumping with NovaSeq 10x MiSeq caveat (Schnell 2015), Hill-number effective species counts with coverage-based rarefaction (Jost 2006; Chao & Jost 2012; doubling rule), beta-diversity decomposition with MANDATORY PERMANOVA + PERMDISP pair (Anderson & Walsh 2013), constrained ordination, and the read-counts-not-abundance critique (Lamb 2019). Use when processing eDNA samples for biodiversity assessment, deciding ASV vs OTU, configuring OBITools3 v3, interpreting decontam screening, or reporting community comparisons with the dispersion confound check.

日本語の概要は準備中です。原文の説明を表示しています。

Assess drug-drug interactions — CYP metabolic interactions (substrate/inhibitor/inducer), transporter (P-gp, BCRP, OATP) effects, pharmacodynamic synergy/antagonism, clinical significance scoring, and management recommendations. Use for polypharmacy review, prescribing decision support, and safety analysis when adding or switching drugs.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.

日本語の概要は準備中です。原文の説明を表示しています。

Drug and chemical toxicity assessment via adverse outcome pathways (AOPs), real-world FAERS adverse event signals, FDA labels, and toxicogenomic associations. Triangulates molecular initiating event to cellular outcome to organ-level toxicity to clinical adverse event. Use for hepatotoxicity/cardiotoxicity/nephrotoxicity prediction and toxicology reports.

日本語の概要は準備中です。原文の説明を表示しています。

Performs retrosynthetic planning using AiZynthFinder (MCTS, template-based), Chemformer (template-free transformer), ASKCOS, and emerging RetroSynFormer with explicit handling of route scoring, building-block availability (eMolecules, Enamine, Mcule), forward prediction validation (Molecular Transformer), and disconnection-aware multi-objective search (MO-MCTS). Use when assessing synthetic feasibility of generated or selected molecules, planning multi-step syntheses, building synthesis-aware design pipelines, or screening libraries for retro-route feasibility.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Multi-method binding pocket detection and druggability assessment. Grid-based, fpocket, and P2Rank detection with druggability scoring, visualization, and cross-structure comparison.

日本語の概要は準備中です。原文の説明を表示しています。

Review Stellar Community Fund (SCF) Build Award applications. Use when evaluating SCF submissions, covering project fit assessment, technical architecture evaluation, team readiness, traction validation, budget analysis, and funding recommendations.

日本語の概要は準備中です。原文の説明を表示しています。

Help teams prepare materials for an SCF referral. Use when a team wants to approach a referrer (SCF Pilot, SDF staff, alumni who completed deliverables, ambassador, or ecosystem partner) with a strong package that makes it easy for the referrer to evaluate and endorse them. Covers the referral form fields, what referrers assess, and how to present your project for referral.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze the competitive landscape for an SCF submission. Identifies similar projects on Stellar and other chains, assesses overlap and differentiation. Use when reviewing or drafting an SCF submission and you need to map similar projects on Stellar and other chains and articulate the differentiation.

日本語の概要は準備中です。原文の説明を表示しています。

Assess organizational AI maturity. TRIGGERS - Use when user needs help with ai-maturity-model related tasks.

日本語の概要は準備中です。原文の説明を表示しています。

Audit existing business processes to identify AI automation opportunities. TRIGGERS - Use when user wants to find AI opportunities, audit processes for automation, or assess AI readiness.

日本語の概要は準備中です。原文の説明を表示しています。

Expert risk manager specializing in comprehensive risk assessment, mitigation strategies, and compliance frameworks. Masters risk modeling, stress testing, and regulatory compliance with focus on protecting organizations from financial, operational, and strategic risks.

日本語の概要は準備中です。原文の説明を表示しています。

Expert security auditor specializing in comprehensive security assessments, compliance validation, and risk management. Masters security frameworks, audit methodologies, and compliance standards with focus on identifying vulnerabilities and ensuring regulatory adherence.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates and implements age estimation and verification technologies for online services. Covers facial age estimation, digital ID verification, self-declaration with risk assessment, AI-based age estimation, and the accuracy versus privacy tradeoff. Includes ICO guidance and euCONSENT framework. Keywords: age verification, age estimation, facial analysis, digital ID, children, online safety.

日本語の概要は準備中です。原文の説明を表示しています。

Specialized reverse engineering analysis workflows for binary analysis, pattern recognition, and vulnerability assessment

日本語の概要は準備中です。原文の説明を表示しています。